Amgen
Corporate Bias Rating
Expand Summary
Risk Level:
Summary:
Amgen is High Risk. The company yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Amgen embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach fails to safeguard free exercise, free speech, and free enterprise.
View Full Corporate Bias Ratings ReportBoard Bias
Expand Summary
CEO of Amgen
Robert A. Bradway
Summary:
Headquartered in Thousand Oaks, California, Amgen is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Robert A. Bradway serves as CEO/President and Chairman, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $880,050 to Republican causes and $476,320 to Democratic causes. Under their tenure, Amgen currently holds a 'High Risk' risk rating.
View Full Board Bias ReportPolitical Contributions of Leadership:
$880,050
$476,320
Republican
Democrat
In the News
Expand Summary
AbbVie , Amgen , Bank of America , Caterpillar , Citigroup , Citizens Financial , Coca-Cola , Colgate-Palmolive , CVS Health , Delta Air Lines , General Motors , JPMorgan Chase , Morgan Stanley , Prudential Financial , Robert Half , Sherwin-Williams , Uber Technologies , UPS , Wells Fargo